BioCardia president and CEO Peter Altman buys $475 in BCDA shares

Peter Altman, President and CEO of BioCardia, Inc. (NASDAQ:BCDA), recently increased his stake in the company through open market purchases totaling 500 shares for a combined value of $475. The transactions occurred on October 15 and October 16, 2026.

On October 15, Mr. Altman acquired 200 shares of BioCardia common stock. These shares were purchased at prices ranging from $0.94 to $0.95 per share. The following day, October 16, he purchased an additional 300 shares of common stock, with prices for these trades ranging from $0.94 to $0.96 per share. The weighted average price for both transactions was reported as $0.95 per share.

Following these direct purchases, Mr. Altman beneficially owns 385,385 shares of BioCardia common stock. The insider buying comes as the stock trades at $1.05, up from a previous close of $0.90, though shares remain down 29% over the past year. According to InvestingPro analysis, BCDA appears fairly valued at current levels. The company holds a "Fair" financial health score of 1.85, and InvestingPro offers 10 additional key tips about BCDA’s financial position, including insights on cash burn and profitability outlook. Investors seeking deeper analysis can access the comprehensive Pro Research Report, available for BCDA and 1,400+ other US equities.

In other recent news, BioCardia Inc. reported a second-quarter loss that was smaller than analysts had anticipated. The company posted an adjusted earnings per share (EPS) loss of $0.13, outperforming the expected loss of $0.18, marking a 27.78% surprise. This development comes alongside significant progress in regulatory approvals, with Japan’s PMDA supporting a Shonin submission for the CardiAMP cell therapy. Additionally, the FDA indicated that the CardiAMP Heart Failure II trial might support pre-market approval, improving BioCardia’s regulatory outlook in the United States.

The company ended the quarter with $5.4 million in cash and cash equivalents, providing a financial runway into 2027. BioCardia’s second quarter also saw lower expenses and steady cash use, with net cash used in operations slightly increasing to $1.7 million from $1.6 million a year earlier. For the first half of the year, operating cash use amounted to $3.4 million, only marginally higher than the same period last year. These recent developments reflect BioCardia’s continued focus on its cell therapy and delivery platform.